High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
There is an urgent need for next-generation COVID-19 vaccines that are safe, demonstrate high protective efficacy against SARS-CoV-2 variants and can be manufactured at scale. We describe a vaccine candidate (CoVac-II) that is based on stabilized, trimeric spike antigen produced in an optimized, scalable and chemically defined production process.
Article activity feed
-
-
SciScore for 10.1101/2021.08.18.456891: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IACUC: ) Animal Ethics and Welfare Committee. Sex as a biological variable Immunization: Female C57BL/6 mice (6-8 weeks of age) were purchased from Australian BioResources Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Cells were surface stained with Fixable Blue Dead Cell Stain (Life Technologies) and marker-specific fluorochrome-labeled antibodies (Supplementary Table 1). marker-specific fluorochrome-labeled antibodies ( Supplementary Table 1suggested: NoneExperimental Models: Cell Lines Sentences Resources full-length spike stabilized, trimeric proteins were expressed in CHO cells and … SciScore for 10.1101/2021.08.18.456891: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IACUC: ) Animal Ethics and Welfare Committee. Sex as a biological variable Immunization: Female C57BL/6 mice (6-8 weeks of age) were purchased from Australian BioResources Randomization not detected. Blinding not detected. Power Analysis not detected. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Cells were surface stained with Fixable Blue Dead Cell Stain (Life Technologies) and marker-specific fluorochrome-labeled antibodies (Supplementary Table 1). marker-specific fluorochrome-labeled antibodies ( Supplementary Table 1suggested: NoneExperimental Models: Cell Lines Sentences Resources full-length spike stabilized, trimeric proteins were expressed in CHO cells and purified as previously described10. CHOsuggested: NoneBriefly, serially-diluted sera (paired pre-immune and immune) and SARS-CoV-2 virus (final MOI of 10) were added to 106/mL Vero cells (ATCC® CCL-81) containing 50 μg/mL of propidium iodide (PI) and plates were then loaded in an IncuCyte S3 high-content imaging system (Essen Bioscience/Sartorius, Ann Arbor, MI) Verosuggested: NoneReplication-deficient SARS-CoV-2 Spike pseudotyped lentivirus particles were generated by co-transfecting GFP-luciferase vector and ancestral4 or Beta18 spike expression constructs with lentivirus packaging and helper plasmids into 293T cells using Fugene HD (Promega) as previously described 22. 293Tsuggested: NoneExperimental Models: Organisms/Strains Sentences Resources Immunization: Female C57BL/6 mice (6-8 weeks of age) were purchased from Australian BioResources C57BL/6suggested: NoneRecombinant DNA Sentences Resources Replication-deficient SARS-CoV-2 Spike pseudotyped lentivirus particles were generated by co-transfecting GFP-luciferase vector and ancestral4 or Beta18 spike expression constructs with lentivirus packaging and helper plasmids into 293T cells using Fugene HD (Promega) as previously described 22. GFP-luciferasesuggested: NoneSoftware and Algorithms Sentences Resources Neutralising antibody titers (expressed as IC50) were obtained from four-parameter logistic curve-fits of cell death profiles using OriginPro 9 (Origin Lab Corp., Northampton, MA) OriginProsuggested: NoneResults from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
